Answers are grounded in this paper and cite their sources.
Framework advocates for improved price negotiations in CMS, integrating health technology assessment and stakeholder engagement.
The Centers for Medicare and Medicaid Services (CMS) can now negotiate the prices of a set of drugs that represent significant Medicare expenditures. The long-term success of negotiations will depend in part on stakeholders' views on the program's transparency and inclusivity. CMS has completed its first round of price negotiations for ten drugs; the prices will become effective on January 1, 2026. For future rounds, we advocate that CMS adopt a different price negotiation approach, one that embodies the best practices of health technology assessment-the discipline that determines a fair drug price in many settings worldwide. Our proposed framework consists of four components: selection of therapeutic alternatives, assessment of the value of the selected drugs, a decision matrix for weighting multiple negotiation factors, and a deliberation on the accumulated clinical and economic evidence by an independent advisory committee. Patient, caregiver, and other stakeholder engagement is integrated in each component.
No takes yet. Share an insight, caveat, or question.
Ollendorf et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: